Huntington initiated coverage of Sabra Health Care REIT stock
Published on 10/08/2026 at 18:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Huntington initiated coverage of Sabra Health Care REIT at Outperform with a USD 23.00 price target on September 10, 2026.
- Second-quarter 2026 revenue reached USD 235.9 million, up 24.7 percent year over year, while diluted earnings per share were negative USD 0.10.
- Sabra guided to normalized FFO of USD 1.53-1.55 per diluted share for 2026, implying 7 percent growth at the midpoint.
- The Lang & Schwarz price was EUR 16.66 on October 8, 2026, down 0.48 percent from the EUR 16.74 prior close.
Sabra Health Care REIT (ISIN US78573L1061) was trading at EUR 16.66 in after-hours trading at Lang & Schwarz on October 8, 2026, down 0.48 percent from the EUR 16.74 prior close. Huntington initiated coverage at Outperform and set a USD 23.00 price target in a note dated September 10, 2026, according to MarketBeat.
Three dated SBRA events
On July 21, 2026, Sabra re-tenanted 26 properties and raised its 2026 adjusted funds from operations guidance, according to MarketScreener. On August 3, 2026, second-quarter revenue reached USD 235.9 million versus a USD 219.4 million FactSet estimate, while adjusted earnings per share missed expectations, the same source reported. On September 10, 2026, Huntington became the latest named analyst to set a USD 23.00 target and an Outperform rating, according to MarketBeat.
What does guidance imply?
Sabra's 2026 guidance calls for normalized funds from operations of USD 1.53-1.55 per diluted share and normalized adjusted funds from operations of USD 1.59-1.61. The midpoint of the normalized FFO range implies 7 percent year-over-year growth, while the normalized AFFO midpoint implies 8 percent growth, according to MarketScreener. That contrast matters: the second-quarter revenue comparison was positive, but the quarter also included a net loss of USD 25.2 million and diluted earnings per share of negative USD 0.10, according to Business Wire.
Next date and valuation context
Sabra's next earnings date is November 4, 2026, according to Yahoo Finance. The Nasdaq-listed healthcare REIT had a market capitalization of USD 4.7 billion on October 8, 2026, while its 52-week range was USD 17.17 to USD 22.77. The current euro quote is therefore EUR 0.51 below the prior close, while the US dollar range places the shares USD 1.47 above the yearly low and USD 4.13 below the yearly high.
Sabra stock remains below its yearly high
Sabra owns and invests in healthcare properties across the United States and Canada. Its second-quarter revenue of USD 235.9 million exceeded the USD 219.4 million estimate by USD 16.5 million, but the negative USD 0.10 diluted earnings per share result shows why the normalized FFO outlook remains central to the valuation debate. The further course of trading is shown by the continuously updated real-time quote of Sabra Health Care REIT stock.
Sabra Health Care REIT stock facts
- Company: Sabra Health Care REIT, Inc.
- ISIN: US78573L1061
- Ticker: SBRA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 8, 2026, 6:33 p.m. CEST): EUR 16.66
- Change versus prior close: minus 0.48 percent
- Prior close Lang & Schwarz (October 7, 2026): EUR 16.74
- Market capitalization: USD 4.7 billion (as of October 8, 2026)
- 52-week range: USD 17.17-22.77 (as of October 8, 2026)
- Sector / Industry: Real Estate / REIT - Healthcare Facilities
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
